

Special Issue

Rare Breast Tumors

Message from the Guest Editors

In most common types of breast cancer, such as no special type and invasive lobular carcinoma, the therapeutic approach is generally well defined. However, rare breast tumors, accounting for less than 2% of all breast cancer cases, present a diagnostic and therapeutic challenge. Because of their rarity, data on prognosis and evidence-based recommendations are lacking and there are no randomized studies to define the optimal neoadjuvant and adjuvant treatment. The goal of this Special Issue is to highlight breast tumors with rare histology, with a focus on clinical and pathological characteristics as well as responses to different therapeutic strategies. Original research articles and reviews are welcome.

Prof.

Guest Editors

Prof. Dr. Maggie Banys-Paluchowski

Department of Gynecology and Obstetrics, University Hospital Schleswig, Holstein Campus Lübeck, 23562 Lübeck, Germany

Prof. Dr. Maria Luisa Gasparri

Centro di Senologia della Svizzera Italiana (CSSI), Department of Gynecology and Obstetrics, Ente Ospedaliero Cantonale, University of Italian Switzerland (USI), Lugano, Switzerland

Deadline for manuscript submissions

25 September 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/196430

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)